Bruce Power and ITM to supply cancer therapy isotope
Bruce Power and ITG, a subsidiary of radiopharmaceutical technology company ITM Isotopen Technologien München (ITM), have launched a joint effort to explore the production of the medical radioisotope lutetium-177 (Lu-177) at Bruce Power's Candu reactors.
Lu-177 is used in targeted
radionuclide therapy to treat cancers like neuroendocrine tumours and prostate
cancer. The medical-grade radioisotope is used to destroy cancer cells while
leaving healthy cells unaffected.
The companies announced the
signature of a Memorandum of Understanding to explore the production of Lu-177
at Bruce, which they say has the ability to meet global supply needs until
2064. The partnership aims to meet the medical community's growing demand for
the radioisotope. Development, processing, and global distribution of Lu-177
will be managed by ITG.
To read more please visit:
Source: World Nuclear News